GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Additional Paid-In Capital

CLDI (Calidi Biotherapeutics) Additional Paid-In Capital : $133.67 Mil(As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Additional Paid-In Capital?


Calidi Biotherapeutics's quarterly additional paid-in capital increased from Sep. 2024 ($107.41 Mil) to Dec. 2024 ($123.28 Mil) and increased from Dec. 2024 ($123.28 Mil) to Mar. 2025 ($133.67 Mil).

Calidi Biotherapeutics's annual additional paid-in capital increased from Dec. 2022 ($19.93 Mil) to Dec. 2023 ($91.38 Mil) and increased from Dec. 2023 ($91.38 Mil) to Dec. 2024 ($123.28 Mil).

Calidi Biotherapeutics Additional Paid-In Capital Historical Data

The historical data trend for Calidi Biotherapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Additional Paid-In Capital Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
11.95 13.32 19.93 91.38 123.28

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.21 100.84 107.41 123.28 133.67

Calidi Biotherapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Calidi Biotherapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Additional Paid-In Capital
Comparable Companies
INAB AFMD ABVC PHGE BIVI EQ MBRX BOLT ZEOX SABS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Website
https://www.calidibio.com
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.